Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.